Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.64M P/E - EPS this Y 98.00% Ern Qtrly Grth -
Income -17.91M Forward P/E -1.66 EPS next Y 70.90% 50D Avg Chg -32.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -76.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -94.00%
Recommedations 2.00 Quick Ratio 0.96 Shares Outstanding 17.27M 52W Low Chg 4.00%
Insider Own 0.05% ROA -207.95% Shares Float 17.26M Beta 0.47
Inst Own 11.46% ROE -1,048.70% Shares Shorted/Prior 278.56K/1.64M Price 2.02
Gross Margin - Profit Margin - Avg. Volume 274,620 Target Price -
Oper. Margin - Earnings Date - Volume 65,494 Change -3.81%
About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.

TransCode Therapeutics, Inc. News
09/17/24 TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
09/10/24 TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
09/05/24 TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
08/15/24 TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
07/24/24 TransCode Therapeutics, Inc. Announces Closing of Public Offering
07/22/24 TransCode Therapeutics, Inc. Announces Pricing of Public Offering
07/22/24 TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
06/10/24 Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
05/29/24 TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
05/13/24 TransCode Therapeutics Open Letter to Shareholders
04/15/24 TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
04/03/24 TransCode Therapeutics Reports 2023 Results; Provides Business Update
03/28/24 TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
03/11/24 TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
03/06/24 TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
08:00 AM TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
01/31/24 Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
01/29/24 TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
01/22/24 TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
01/19/24 TransCode (RNAZ) Down 50% on Issue of New Common Stock
RNAZ Chatroom

User Image ZJ3001 Posted - 37 minutes ago

$RNAZ 👇🏾

User Image ZJ3001 Posted - 38 minutes ago

$RNAZ- wow! Look at those numbers! Cure for cancer!

User Image ZJ3001 Posted - 39 minutes ago

$RNAZ Patented technology! Important to lock down patents before fda approval so no one can beat you to the finish line!

User Image ZJ3001 Posted - 41 minutes ago

$RNAZ completely absorbed in the cancer cell almost immediately.

User Image ZJ3001 Posted - 43 minutes ago

$RNAZ proprietary delivery!

User Image ZJ3001 Posted - 45 minutes ago

$RNAZ metastatic cancer is the cause of ~90% of all cancer death’s worldwide. Trsnscode is the only one with a patented nano delivery system that is 99% absorbed by the tumor. Can be used on multiple cure. The most difficult part of a cure, specifically mAbs, is they are absorbed by the whole body and need to be “overdosed” to have minimal impact. Unlike RNAZ!

User Image ZJ3001 Posted - 10 hours ago

$RNAZ https://ir.transcodetherapeutics.com/news-releases/news-release-details/transcode-therapeutics-reports-positive-data-first-human

User Image SadyK189 Posted - 11 hours ago

Here is my Amazing daily Stocktwits report 1 / 2: $LUCY Price 8.20. My post last night "looking good on daily chart. Key support at 6.15 - 6.45. Next key level to test is 8.9 - 9.35" It hit our desired zone, went till 9.98 today $APLT My post last night "Strong close of daily candle. Key support at 6.2 - 6.6. Looking good to test next key level at 8.75 - 9.15" It hit our desired zone, went till 8.86 today $SMSI Price $1. My post on Tuesday "Looking good on 4hours chart. 0.85 - 0.9 is acting as key support zone. It can test 1.20 - 1.35 zone again." It went till 1.47 today $RNAZ Price 0.32. My post last night "looking good on 4hours chart. Currently at 0.3358. Key support at 0.27 - 0.29. It can test and break 0.4 again" It went till 0.4335 today $XCH Price 18.95. My post last night "looking good on daily chart. Key support at 12 - 14. Next key level to test is 23 - 25. Currently at 18.95" It went till 25.17 today

User Image ZJ3001 Posted - 14 hours ago

$RNAZ https://x.com/medarovazdravka/status/1587861823302537216?s=46&t=00OsdJCdiHHxO5kudlyfzg

User Image ZJ3001 Posted - 14 hours ago

$RNAZ this has more details on TTX-MC138, and why this is a hold! Big Pharma contract incoming. https://ir.transcodetherapeutics.com/news-releases/news-release-details/transcode-therapeutics-announces-publication-new-data-supporting/

User Image techjerk Posted - 16 hours ago

$RNAZ higher highs last few days ..

User Image supersaiyansteve Posted - 16 hours ago

$RNAZ barely on radars this morning and gap to fill upto .80

User Image phantomtrader75 Posted - 17 hours ago

$RNAZ

User Image Drizzyman Posted - 17 hours ago

$RNAZ May 29 2024 PR quote: "Full data analysis is ongoing and will be included in the final study report." We have yet to receive an update with this data, and the Phase 1/2 trials proceeded. This data should be out soon IMHO.

User Image Wallymarket Posted - 18 hours ago

$VCIG next month will be EPIC ✌️ $SGN $VERO $HOLO $RNAZ

User Image phantomtrader75 Posted - 19 hours ago

$RNAZ STOP SELLING!!! $50 let’s go!!!

User Image investorTim Posted - 19 hours ago

$RNAZ

User Image ibrar Posted - 19 hours ago

$RNAZ Beautiful stock,making a very beautiful drug,but a very long way,needs alot of money to complete other phases..check out this $VCIG beauty..CEO buying + stock repurchase in coming months+ next month launching their own GPU brand in malaysia.

User Image investorTim Posted - 19 hours ago

$RNAZ let’s go

User Image investorTim Posted - 20 hours ago

$RNAZ 🚀

User Image investorTim Posted - 20 hours ago

$RNAZ

User Image Luna1997 Posted - 20 hours ago

$RNAZ she shining bright 👏👏👏

User Image dogood Posted - 21 hours ago

$RNAZ once it hits .50 watch we hit $1.75 fast

User Image ZJ3001 Posted - 21 hours ago

$RNAZ https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.e15072

User Image ZLUCIAN Posted - 21 hours ago

$RNAZ This will fly soon. Longs prepare your seatbelts. Shorts prepare to cover your positions. Let's goooooooo!!

User Image SadyK189 Posted - 21 hours ago

$RNAZ Price 0.32. Mentioned it can test and break 0.4 last night. It went till 0.4335 today

User Image Drizzyman Posted - 22 hours ago

$RNAZ Looks like the same pattern from back in April before the run to $2. They cannot RS on this and have a Nasdaq hearing panel scheduled for 10/1. If it runs to over $1, they could use that as an argument to stay listed even if they do not meet the 10 day minimum. Compliance, would rocket this stock, as that seems to be an on going pattern with compliance gains as of late. Outside of that, based on the science alone and a possible stop to Metastatic cancer, ummm yea, this has insane potential. IMHO

User Image Trissy08 Posted - 22 hours ago

$RNAZ rocketed up to 0.44 then dropped hard. I guess sellers locking in profit. Damn then :)

User Image Procdeez Posted - 22 hours ago

$RNAZ scaling into BCTX now

User Image Trissy08 Posted - 22 hours ago

$RNAZ nice to see the 0.40’s Now fill that gap up around the 0.80’s please.

Analyst Ratings
HC Wainwright & Co. Buy Sep 6, 24
HC Wainwright & Co. Buy Aug 15, 24
HC Wainwright & Co. Buy May 29, 24
HC Wainwright & Co. Buy May 16, 24
HC Wainwright & Co. Buy Apr 16, 24
HC Wainwright & Co. Buy Apr 3, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fitzgerald Thomas A Chief Financial Offi.. Chief Financial Officer Sep 28 Buy 0.51 49,350 25,168 56,318 10/02/23
Dudley Robert Michael Chief Executive Offi.. Chief Executive Officer Sep 28 Buy 0.51 98,000 49,980 180,262 10/02/23
Dudley Robert Michael Chief Executive Offi.. Chief Executive Officer Jun 20 Buy 2.6 18,607 48,378 82,262 06/22/23
Dudley Robert Michael Chief Executive Offi.. Chief Executive Officer Jun 09 Buy 2.76 19,000 52,440 912,114 06/13/23
Dudley Robert Michael Chief Executive Offi.. Chief Executive Officer Sep 14 Buy 1.15 20,000 23,000 893,114 09/16/22